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Abstract
b-Site APP-cleaving enzyme 1 (BACE1) initiates amyloid-b (Ab) generation and thus represents a prime therapeutic target in
treating Alzheimer’s disease (AD). Notably, increasing evidence indicates that BACE1 levels become elevated in AD brains as
disease progresses; however, it remains unclear how the BACE1 upregulation may affect efficacies of therapeutic
interventions including BACE1-inhibiting approaches. Here, we crossed heterozygous BACE1 knockout mice with AD
transgenic mice (5XFAD model) and compared the abilities of partial BACE1 reduction to rescue AD-like phenotypes at
earlier (6-month-old) and advanced (15–18-month-old) stages of disease, which expressed normal (,100%) and elevated
(,200%) levels of BACE1, respectively. BACE1
+/2 deletion rescued memory deficits as tested by the spontaneous alternation
Y-maze task in 5XFAD mice at the earlier stage and prevented their septohippocampal cholinergic deficits associated with
significant neuronal loss. Importantly, BACE1
+/2 deletion was no longer able to rescue memory deficits or cholinergic
neurodegeneration in 5XFAD mice at the advanced stage. Moreover, BACE1
+/2 deletion significantly reduced levels of Ab42
and the b-secretase-cleaved C-terminal fragment (C99) in 6-month-old 5XFAD mouse brains, while these neurotoxic
b-cleavage products dramatically elevated with age and were not affected by BACE1
+/2 deletion in 15–18-month-old 5XFAD
brains. Interestingly, although BACE1
+/2 deletion lowered BACE1 expression by ,50% in 5XFAD mice irrespective of
age in concordance with the reduction in gene copy number, BACE1 equivalent to wild-type controls remained in
BACE1
+/2?5XFAD mice at the advanced age. In accord, phosphorylation of the translation initiation factor eIF2a,a n
important mediator of BACE1 elevation, was dramatically increased (,9-fold) in 15–18-month-old 5XFAD mice and
remained highly upregulated (,6-fold) in age-matched BACE1
+/2?5XFAD mice. Together, our results indicate that partial
reduction of BACE1 is not sufficient to block the phospho-eIF2a-dependent BACE1 elevation during the progression of AD,
thus limiting its abilities to reduce cerebral Ab/C99 levels and rescue memory deficits and cholinergic neurodegeneration.
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Introduction
Although the cause of Alzheimer’s disease (AD) has not been
completely understood, there is increasing consensus that
accumulation of the amyloid-b (Ab) peptide plays a central role
in triggering a pathogenic cascade ultimately leading to neuronal
death and profound memory deficits [1,2]. Therefore, the b-
secretase (BACE1: b-site amyloid precursor protein cleaving
enzyme 1), which is responsible for initiating the production of
Ab, represents an excellent therapeutic target for the treatment of
AD [3,4,5,6]. This view is strongly supported by a growing body of
evidence that genetic deletion of BACE1 prevents AD-like
pathologies and improves cognitive impairments in different
transgenic mouse models [7,8,9,10]. However, since the discovery
of BACE1, medicinal chemistry toward the development of
efficacious inhibitors has proved to be a challenging task
[11,12,13,14,15]. In particular, the larger active site of BACE1
renders it extremely difficult to inhibit this aspartic protease with
small-molecule compounds that can pass the blood-brain barrier.
Given that central lowering of Ab levels following systemic
administration of future BACE1 inhibitor drugs may be limited
[16,17], it is important to determine the degree of BACE1
suppression that is required to exert therapeutic benefits including
memory improvements during the progression of AD.
Studies from our laboratory and others applied genetic or
immunization-based approaches to demonstrate that partial reduc-
tion of BACE1 suffices to attenuate Ab-related pathology and rescue
synaptic and memory deficits in mouse models of AD
[18,19,20,21,22]. However, these beneficial effects of partial BACE1
suppression were tested using relatively earlier stages of APP
transgenic mice in which behavioral and synaptic phenotypes have
just started to emerge. It remains unclear whether partial BACE1
inhibition remains disease-modifying and can improve functional
defects throughout the progression of AD. Notably, evidence is
accumulating that BACE1 expression and activity levels are
significantly elevated in sporadic AD brains, which is considered a
crucial contributing factor in the pathogenesis of this enigmatic
disease[23,24,25,26,27]. This raises a possibility that the same degree
of BACE1 suppression may be less effective or ineffective at the
advanced phase of AD that is accompanied by BACE1 upregulation.
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amyloid model that co-overexpresses human amyloid precursor
protein (APP) and presenilin-1 (PS1) harboring five familial AD
(FAD) mutations [8,28]. 5XFAD mice begin to develop visible
amyloid deposition as early as 2 months of age and exhibit
memory declines on hippocampus-dependent tasks between 4–6
months with moderate Ab accumulation [8,28,29,30,31]. These
behavioral phenotypes coincide with the onset of hippocampal
synaptic dysfunction at Schaffer collateral-CA1 pathways in
5XFAD mice [29]. At $9 months of age, 5XFAD mice show
severe memory deficits together with further developed Ab
pathology and marked synaptic degeneration and neuronal loss
[9,21,28,30,31]. Of particular interest, elevations in BACE1 levels
(,2-fold) have been demonstrated to occur in brains of 5XFAD
mice as amyloid pathology progresses [9,21,26]. Furthermore,
recent studies suggest that phosphorylation of the eukaryotic
translation initiation factor-2a (eIF2a) plays an important role in
mediating the post-transcriptional upregulation of BACE1 in
human AD and 5XFAD mouse brains [32,33]. In this study, we
compared the abilities of 50% BACE1 reduction with heterozy-
gous gene deletion to suppress b-amyloidogenesis and AD-like
phenotypes in the 5XFAD transgenic mouse model at earlier (6-
month-old) and advanced (15–18-month-old) stages, which show
normal and increased levels of BACE1 expression in brains,
respectively. Our results clearly indicate that the efficacies of
BACE1
+/2 deletion in reducing Ab and C99 accumulation and
rescuing cholinergic neurodegeneration and memory deficits
become smaller or disappear as disease progresses into the more
severe stage with marked elevations in phospho-eIF2a and BACE1
levels in 5XFAD mice.
Results
Abilities of partial BACE1 reduction to rescue memory
dysfunction decline with age in 5XFAD mice
To compare efficacies of BACE1
+/2 deletion in improving
memory impairments in 5XFAD transgenic mice at 6 and 15–18
months of age, we tested the mice with a hippocampus-dependent
learning paradigm, spontaneous alternation in the Y-maze that
represents a measure of spatial working memory [34] (Fig. 1). A
one-way ANOVA revealed significant differences in percent
alternation between the four groups of mice tested at 6 months
of age (F(3,32)=4.78, p,0.05) (Fig. 1A). Notably, 5XFAD mice
showed significantly reduced levels of spontaneous alternation
performance in the Y-maze compared with wild-type controls
(p,0.05), while the spatial working memory deficits were rescued
Figure1.Age-relatedeffects ofBACE1
+/2 deletiononmemorydeficitsin5XFADmice.Memory functionofmiceat6months(A,C) and15–18
months (B, D) of age was tested using the spontaneous alternation Y-maze task. (A, B) Spatial working memory, as assessed by the spontaneous
alternation performance, is significantly impaired (around 50% chance levels) in 5XFAD mice irrespective of age compared to wild-type controls
(*p,0.05). Note thatBACE1
+/2?5XFADarerescuedcompletelyback towild-type levelsof alternationperformanceat6 months but not at15–18months
of age (
# p,0.05versus age-matched 5XFAD). n=5–12 mice pergroup. (C, D) Total number of arm entries reflecting exploratory activities of mice in the
Y-maze does not differ between the four groups irrespective of age. n=5–12 mice per group. All data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0012974.g001
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+/2 genotype,
which exhibited significantly higher spontaneous alternation than
did 5XFAD mice (p,0.05). In contrast, when mice were tested at
15–18 months of age, levels of spontaneous alternation was
similarly reduced in 5XFAD and BACE1
+/2?5XFAD mice
compared with those of age-matched wild-type control mice
(F(3,33)=11.38, p,0.05) (Fig. 1B). Post-hoc Fisher’s PLSD test
revealed no significant difference in alternation performances
between 5XFAD and BACE1
+/2?5XFAD mice (p=0.24), indi-
cating that BACE1
+/2 deletion failed to improve the spatial
working memory defect in 5XFAD mice at this advanced age.
Meanwhile, the percent alternation was indistinguishable between
BACE1
+/2 and wild-type mice at 6 or 15–18 months of age,
demonstrating that BACE1
+/2 mice were normal in spatial
working memory function in contrast to BACE1
2/2 mice that
exhibited poor spontaneous alternation performance in the Y-
maze in our previous studies [7,9]. Furthermore, the total number
of arm entries during Y-maze testing was not significantly different
between the four groups of mice tested at 6 months (Fig. 1C) or
15–18 months (Fig. 1D) of age. Therefore, levels of exploratory
activity were not affected in these mice including BACE1
+/2 mice,
which was also in contrast with the hyperactivity of BACE1
2/2
mice during Y-maze testing [7,9]. Together, BACE1
+/2 gene
deletion was able to more specifically improve memory dysfunc-
tion in 5XFAD mice; however, the memory benefit produced by
partial reduction of BACE1 was observed in an age-related
manner and disappeared as disease progressed into the more
severe phase in 5XFAD mice.
Abilities of partial BACE1 reduction to rescue cholinergic
neurodegeneration decline with age in 5XFAD mice
The septohippocampal cholinergic pathway hasan established role
in mediating spatial working memory including spontaneous
alternation performance in the Y-maze [35,36,37]. To address
mechanisms underlying the age-dependent beneficial effects of
BACE1
+/– deletion on memory, we compared levels of choline
acetyltransferase (ChAT), a marker of cholinergic neurons, between
wild-type, 5XFAD and BACE1
+/2?5XFAD mice (Fig. 2). First,
immunoblot analysis of hippocampal homogenate samples demon-
strated that ChAT levels were significantly reduced in 5XFAD mice
at 6 months of age compared with wild-type controls, while ChAT
was restored to wild-type levels in 5XFAD mice with BACE1
+/2
genotype (F(2,18)=8.89, p,0.05) (Fig. 2A).In contrast, ChAT levels in
the hippocampus of both 5XFAD and BACE1
+/2?5XFAD mice at
15–18 months of age were significantly lower than those of wild-type
control mice (F(2,24)=10.51, p,0.05) (Fig. 2B). Post-hoc Fisher’s PLSD
test indicated only a trend toward slight increases in ChAT levels of
BACE1
+/2?5XFAD mice compared to those of 5XFAD littermates
(p=0.10). Therefore, consistent with age-related improvements in the
memory performance, the effects of BACE1
+/2 deletion in rescuing
hippocampal cholinergic dysfunction were significant in 6-month-old
5XFAD mice but not in 15–18-month-old 5XFAD mice.
To determine whether reductions in hippocampal ChAT
protein levels were associated with degeneration of cholinergic
neurons, we analyzed ChAT-immunoreactive neurons in the
medial septum and the vertical limb of the diagonal band (Ch1/2)
that provide the cholinergic innervation to the hippocampus.
Remarkably, ChAT-positive neurons were less stained in these
brain regions of 5XFAD mice at 6 months (Fig. 2C) and 15–18
months (Fig. 2D) of age as compared with the respective age-
matched wild-type control mice. Quantitative analysis of ChAT-
immunoreactive neurons revealed significant reductions in their
number in 5XFAD mice at 6 months of age compared to wild-type
controls, while ChAT-positive neuron number was completely
restored to wild-type levels in BACE1
+/2?5XFAD mice
(F(2,13)=9.80, p,0.05) (Fig. 2C). In parallel with changes in
hippocampal ChAT levels, the number of ChAT-immunoreactive
neurons in 5XFAD and BACE1
+/2?5XFAD mice at 15–18
months of age was significantly lower than that of wild-type
control mice (F(2,13)=8.49, p,0.05) and was indistinguishable
from each other according to post-hoc Fisher’s PLSD test (p=0.32).
(Fig. 2D). Taken collectively, the abilities of BACE1
+/2 ablation to
prevent degeneration of septohippocampal cholinergic neurons
also diminished with age in 5XFAD mice consistent with changes
in its beneficial effects against memory deficits.
Age-related effects of partial BACE1 reduction on APP
processing and Ab levels in 5XFAD mice
To address molecular basis for the age-dependent benefits of
partial BACE1 reduction against mnemonic and cholinergic
dysfunction, we first examined how the impacts of BACE1
+/2
deletion on APP processing and Ab levels would change in
5XFAD mice as they age (Fig. 3). Western blot analysis of
hemibrain homogenates from 5XFAD and BACE1
+/2?5XFAD
mice (Fig. 3A) demonstrated that the full-length APP expression
levels were not affected by BACE1
+/2 mutation in 5XFAD mice
at 6 months or 15–18 months of age (Fig. 3B). Levels of the b-
secretase-cleaved C-terminal fragment (C99) were significantly
reduced in BACE1
+/2?5XFAD mice at 6 months of age as
compared to 5XFAD mice (F(1,10)=7.37, p,0.05) (Fig. 3C).
Interestingly, C99 levels in 15–18-month-old 5XFAD mouse
brains were significantly higher than those of 6-month-old 5XFAD
brains (,172%) (F(1,10)=10.71, p,0.05), while the elevated levels
of C99 were no longer significantly affected by BACE1
+/2
deletion at this advanced age (F(1,9)=2.57, p=0.14).
We next performed sandwich ELISA to measure cerebral Ab42
levels (Fig. 3D). Ab42 accumulation was also dramatically
exacerbated in 5XFAD mice from 6 to 15–18 months of age
(F(1,6)=48.41, p,0.05). Consistent with changes in C99 levels,
BACE1
+/2 ablation significantly lowered excessive levels of Ab42
in 6-month-old 5XFAD mouse brains (F(1,6)=23.53, p,0.05). In
contrast, Ab42 levels were not significantly different between
BACE1
+/2?5XFAD and 5XFAD mice at 15–18 months of age
(F(1,6)=2.23, p=0.19). Together, biochemical analyses demon-
strated that BACE1
+/2 deletion significantly suppressed the b-
cleavage of APP in 5XFAD mice at 6 months of age resulting in
reduced levels of C99 and Ab42 (by ,53% and ,67%,
respectively), while it was no longer able to significantly influence
levels of these b-products in 15–18-month-old 5XFAD mouse
brains (,18% and ,20% reductions, respectively).
Age-related effects of partial BACE1 reduction on BACE1
and phospho-eIF2a levels in 5XFAD mice
To elucidate the mechanisms by which levels of the b-cleavage
products became less sensitive to reductions by BACE1
+/2
deletion in 5XFAD mice with age, we compared changes in
BACE1 levels in these mouse brain samples (Fig. 4). BACE1 levels
were not different between 5XFAD and wild-type mice at 6
months of age, while BACE1
+/2 genotype significantly reduced
BACE1 expression (by ,50%) in concordance with the reduction
in gene copy number in 5XFAD mice at this age (F(2,18)=11.25,
p,0.05) (Fig. 4A). Meanwhile, BACE1 levels in 15–18-month-old
5XFAD mice were significantly increased up to ,200% of those
found in age-matched wild-type control mice (F(2,11)=31.91,
p,0.05) (Fig. 4B). Heterozygous gene knockout also reduced
cerebral BACE1 expression by ,50% in 5XFAD mice at this
advanced age (p,0.05). However, the residual levels of BACE1 in
Benefits of BACE1
+/2 KO in AD
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12974older BACE1
+/2?5XFAD mouse brains were equivalent to those
of wild-type controls.
These data suggest that the ablation of a single BACE1 allele is
not sufficient to prevent BACE1-elevating mechanisms, thus
maintaining wild-type levels of this enzyme (i.e., twice the gene
copy number) in BACE1
+/2?5XFAD mice at 15–18 months of age.
To test this hypothesis, we compared the abilities of BACE1
+/2
reduction to affect phosphorylation of the translation initiation
factor eIF2a, one of the proposed mediators of BACE1 elevation
associated with AD [32,33], in 5XFAD mice at two different ages
Figure 2. Age-related effects of BACE1
+/2 deletion on cholinergic neurodegeneration in 5XFAD mice. (A, B) Immunoblot analysis of
ChAT in hippocampal lysates from wild-type mice and 5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype. Intensities of ChAT-immunoreactive bands
of mice at 6 months (A) and 15–18 months (B) of age were quantified by phosphorimaging and expressed as percentage of wild-type levels (n=6–9
mice per group). (C, D) Brain sections from wild-type mice and 5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype were immunostained for ChAT.
Shown are representative photomicrographs of ChAT-immunoreactive neurons in the medial septum of mice at 6 months (C) and 15–18 months (D)
of age. Scale bar =200 mm. The number of ChAT-positive neurons in the medial septum and the vertical limb of the diagonal band (Ch1/2), which
provide the cholinergic innervation to the hippocampus, was counted for quantification (n=4–7 mice per group). Both ChAT measures are
significantly reduced in 5XFAD mice irrespective of age as compared with wild-type controls (* p,0.05). Note that ChAT is restored completely back
to wild-type levels in BACE1
+/2?5XFAD mice at 6 months but not at 15–18 months of age (
# p,0.05 versus age-matched 5XFAD). All data are
presented as mean 6 SEM.
doi:10.1371/journal.pone.0012974.g002
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phospho-eIF2a level was marginal and it was completely abolished
in BACE1
+/2?5XFAD mice (F(2,11)=25.76, p,0.05) (Fig. 5A).
Notably, phospho-eIF2a levels were dramatically elevated (,9-fold
relative to wild-type controls) in 15–18-momth-old 5XFAD mouse
brains in accordance with their remarkable BACE1 elevation
(F(2,21)=11.72, p,0.05) (Fig. 5B). Although phospho-eIF2a levels in
BACE1
+/2?5XFAD mice were lower than those of 5XFAD mice at
this advanced age (p,0.05), they remained strikingly elevated
compared with wild-type controls (,6-fold) consistent with the
persistent BACE1 upregulation.
To address the direct relationship between phospho-eIF2a and
BACE1 elevations, we further examined whether phosphorylation
of eIF2a could actually cause an increase in BACE1 levels in
5XFAD mice (Fig. 5C). Brain slices were prepared from 6-month-
old 5XFAD mice that showed only marginal increases in phospho-
eIF2a without any change in BACE1 levels. These slices were
incubated for 1 h in normal aCSF medium or aCSF containing
30 mM Sal 003, a specific and cell-permeable inhibitor of
phosphatase that dephosphorylates phospho-eIF2a. Remarkably,
we found that Sal 003-induced increases in phospho-eIF2a
elevated BACE1 levels, demonstrating that BACE1 is a direct
translational target of the activated phospho-eIF2a pathway in the
5XFAD mouse model of AD.
Discussion
Emerging evidence suggests that partial reduction of BACE1,
which is induced by BACE1
+/2 gene deletion [21,22], siRNA
targeting BACE1 [18] and immunization with BACE1 ectodo-
main [19], can diminish brain Ab levels and amyloid-related
pathologies and improve synaptic and cognitive dysfunctions in
different APP transgenic mice. Although these studies clearly
demonstrate that a complete abolishment of BACE1 activities or
Ab production is not required for functional improvements, it has
not been examined whether the beneficial effects of partial BACE1
suppression may remain unchanged during highly advanced stages
of AD. This is a crucial question for reasoning the b-secretase-
inhibiting approaches in clinical settings. Given ,50% BACE1
suppression generally accepted as it is likely efficacious, we used
Figure 3. Age-related effects of BACE1
+/2 deletion on APP processing and Ab levels in 5XFAD mice. (A) Immunoblot analysis of
hemibrain lysates from 5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype at 6 months and 15–18 months of age. (B, C) Intensities of immunoreactive
bands for full-length APP (B) and C99 (C) were quantified by phosphorimaging and expressed as percentage of 6-month-old 5XFAD mouse levels
(n=5–7 mice per group). (D) Levels of total Ab42 were quantified by sandwich ELISA of guanidine extracts of hemibrain samples and expressed in
nanograms per milligram of total protein (n=4 mice per group). APP overexpression levels are not changed in BACE1
+/2?5XFAD mice irrespective of
age as compared to 5XFAD mice. Levels of C99 and Ab42 are significantly lower in BACE1
+/2?5XFAD mice at 6 months of age as compared with
5XFAD wild-type controls (
# p,0.05). Note that C99 and Ab42 levels are significantly elevated in 15–18-month-old 5XFAD mouse brains compared to
6-month-old 5XFAD brains (* p,0.05), while BACE1
+/2 deletion is no longer able to reduce levels of the b-cleavage products in 5XFAD mice at the
advanced age. All data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0012974.g003
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+/2 mice as a model system to evaluate the efficacies of
partial and therapeutic inhibition of BACE1. We report here that
BACE1
+/2 deletion is able to reduce cerebral Ab42 and rescue
deficits of 5XFAD mice in hippocampus-dependent spatial
working memory in the spontaneous alternation Y-maze assay
when tested at the relatively earlier stage (6 months of age), which
develops moderate plaque pathology but shows no changes in
BACE1 levels. In contrast, BACE1
+/2 deletion is no longer
sufficient to rescue memory impairments or affect Ab42 levels in
5XFAD mice as disease progresses into the more severe
pathological stage (15–18 months of age) that is accompanied by
robust Ab burden and BACE1 elevation. It is important to note
that complete deletion of BACE1 (BACE1
2/2), which abrogates
Ab production, can still rescue impaired spontaneous alternation
performance concomitant with the prevention of Ab deposition
and neuronal loss in 5XFAD mice at this advanced age [9].
Therefore, it seems reasonable to conceive that BACE1 levels
represent a key factor to determine the degree of Ab-dependent
deterioration of memory performance in the 5XFAD mouse
model.
Consistent with our observations, previous studies also showed
that the effects of BACE1
+/2 deletion in reducing total Ab levels
and plaque load in PDAPP transgenic mice become smaller during
the course of disease progression [20]; however, the underlying
mechanisms or functional consequences have not been investigat-
ed. We demonstrated that heterozygous gene knockout lowered
BACE1 expression by ,50% in 5XFAD mice at both earlier (6-
month-old) and advanced (15–18-month-old) stages in concor-
dance with the reduction in gene copy number. Importantly,
BACE1 levels that remained in 15–18-month-old BACE1
+/2?
5XFAD mouse brains were equivalent to those of wild-type
controls. Therefore, if disease progresses into the more profound
stage with BACE1 elevation, deleting a single BACE1 allele is not
sufficient to block the BACE1-elevating mechanisms. This is most
likely to account for the preservation of wild-type levels of this
enzyme (i.e., twice the gene copy number) in the older 5XFAD
mice with BACE1
+/2 genotype. The preserved elevation of
BACE1 allows the continued acceleration of b-cleavage of APP in
BACE1
+/2?5XFAD mice, which would weaken the abilities of
partial BACE1 reduction to suppress Ab accumulation in brain
and improve memory during the advanced phase of disease
progression.
Several mechanisms are proposed to induce the BACE1
elevation associated with AD; for example, caspase-3-dependent
inactivation of GGA3 leading to decreased lysosomal degradation
of BACE1 [38,39], increased phosphorylation of the translation
initiation factor eIF2a [33], transcriptional upregulation mediated
by p25/cyclin-dependent kinase 5 [40,41] and changes in
microRNA expression profiles [42,43]. Importantly, phospho-
eIF2a is demonstrated to be a critical mediator of the post-
transcriptional BACE1 upregulation in sporadic AD and 5XFAD
mouse brains [33]. It is hypothesized that Ab accumulation
induces BACE1 through the phospho-eIF2a pathway in plaque-
surrounding neurons of 5XFAD model mice while the BACE1
elevation further accelerates Ab generation, thus forming positive
feedback pathogenic mechanisms [26,44]. Therefore, we mea-
sured phospho-eIF2a levels in relation to the changes in BACE1
levels observed in BACE1
+/2?5XFAD mice at two different ages.
5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype at 6
months of age showed only marginal or no increase in phospho-
eIF2a levels consistent with their normal levels of BACE1 that
matched the gene copy number. In contrast, phospho-eIF2a levels
were dramatically increased (,9-fold relative to wild-type controls)
in 15–18-momth-old 5XFAD mouse brains. Remarkably, the
phospho-eIF2a upregulation was attenuated to a certain degree
but was largely maintained (,6-fold) in BACE1
+/2?5XFAD mice
at this advanced age. Therefore, it is conceivable that the highly
increased levels of phospho-eIF2a may account for the preserved
Figure 4. Age-related changes in BACE1 levels and the modification by BACE1
+/2 deletion in 5XFAD mice. (A, B) Immunoblot analysis of
BACE1 in hemibrain lysates from wild-type mice and 5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype. Intensities of BACE1-immunoreactive bands
of mice at 6 months (A) and 15–18 months (B) of age were quantified by phosphorimaging and expressed as percentage of wild-type levels (n=4–8
mice per group). BACE1
+/2 deletion reduced BACE1 expression by ,50% in 5XFAD mice irrespective age as compared with age-matched 5XFAD mice
(
# p,0.05). However, since BACE1 expression is significantly elevated up to ,200% in 15–18-month-old 5XFAD mouse brains (* p,0.05 versus wild-
type), levels of BACE1 equivalent to wild-type controls remain in BACE1
+/2?5XFAD brains at the advanced age. All data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0012974.g004
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twice the gene copy number), in the older BACE1
+/2?5XFAD
mice. This idea is strongly supported by our observation that
directly raising levels of phospho-eIF2a with the specific
phosphatase inhibitor Sal 003 elevated BACE1 levels in 6-
month-old 5XFAD mouse brains. Taken together, these results
indicate that the rise in phospho-eIF2a underlies the age-
dependent increase in BACE1 in 5XFAD mice and that the
persistent upregulation of BACE1 through the greater phosphor-
ylation of eIF2a can limit the abilities of partial BACE1 reduction
to suppress Ab accumulation in 5XFAD mouse brains during the
course of disease progression. This mechanism is likely to
contribute to dampening and eventually abolishing the beneficial
effects of BACE1
+/2 deletion against memory deficits.
BACE1
+/2 deletion partially suppressed build-up of the b-
secretase-cleaved C-terminal fragment C99 (by ,53%) correlating
with ,50% BACE1 reductions in 5XFAD mice at 6 months of age.
Meanwhile,C99 levelsincreased substantiallyin 5XFAD mice at 15–
18 months of age (,172%) compared with 6-month-old 5XFAD
mice in line with the BACE1 elevation (,200%). Although
heterozygous knockout also reduced BACE1 expression by ,50%
in 15–18-month-old5XFAD mice in concordance with the reduction
in gene copy number, their C99 levels were not significantly lower
than age-matched 5XFAD levels. These results indicate a dissociation
b e t w e e nC 9 9a n dB A C E 1l e v e l si nt h eo l d e rB A C E 1
+/2?5XFAD
mousebrains.Since C99 isa directb- c l e a v a g em e t a b o l i t eo fA P P ,t h e
high residual levels of C99 may reflect some accumulating species of
C 9 9( s i m i l a rt oA b peptides) that could be less sensitive to reduction
by BACE1
+/2 deletion in 15–18-month-old 5XFAD mice. Interest-
ingly, transgenic overexpression or central administration of the
potentially amyloidogenic C99 fragments has been reported to
induce memory defects and neurodegeneration [45,46,47,48,49].
Therefore, it seems plausible that failure of BACE1
+/2 deletion to
rescue memory deficits in 5XFAD mice at the advanced phase may
be attributable to the high residual levels of neurotoxic C99 fragments
in addition to Ab42 peptides in brain.
Figure 5. Age-related changes in phospho-eIF2a levels and the modification by BACE1
+/2 deletion in 5XFAD mice. (A, B) Immunoblot
analysis of phospho-eIF2a (p-eIF2a) in hemibrain lysates from wild-type mice and 5XFAD mice with BACE1
+/+ or BACE1
+/2 genotype. Intensities of p-
eIF2a-immunoreactive bands of mice at 6 months (A) and 15–18 months (B) of age were quantified by phosphorimaging and expressed as
percentage of wild-type levels (n=4–9 mice per group). While changes in p-eIF2a levels are marginal at 6 months of age, p-eIF2a levels are
dramatically elevated in 15–18-month-old 5XFAD (,9-fold relative to wild-type controls) and BACE1
+/2?5XFAD (,6-fold) mouse brains. * p,0.05
versus wild-type,
# p,0.05 versus 5XFAD. All data are presented as mean 6 SEM. (C) After brain slices from 6-month-old 5XFAD mice were exposed
to normal aCSF or Sal 003-containing aCSF (30 mM), they were lysed for immunoblot analysis. The eIF2a phosphatase inhibitor Sal 003-induced
increase in p-eIF2a level caused the elevation of BACE1 in 5XFAD mouse brains.
doi:10.1371/journal.pone.0012974.g005
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[50], several APP transgenic mouse models reproduce cholinergic
neurodegeneration as evidenced by dystrophic neurites, decreased
fiber density in the hippocampus and cortex, and reductions in the
medial septum and basal forebrain neuron volume/number
[51,52,53,54]; however, the mechanisms for cholinergic neuron
loss is yet largely unknown. 5XFAD model mice exhibited
hippocampal cholinergic deficits associated with significant neuron
loss in the medial septum and the vertical limb of the diagonal
band. Importantly, we found that BACE1
+/2 deletion restored the
cholinergic defects to normal consistent with improvements in
hippocampal spatial memory function in 5XFAD mice at 6
months of age. The results not only provide the first demonstration
that partial suppression of BACE1 is effective in preventing
cholinergic neurodegeneration associated with AD but also
indicate that neurotoxic Ab42 and/or C99 species are responsible
for killing cholinergic neurons. It should also be noted that levels of
the full-length APP were not altered in BACE1
+/2?5XFAD mice,
suggesting that merely overexpressing multiple FAD mutant forms
of APP is unlikely to cause cholinergic or cognitive defects in
5XFAD mice. Meanwhile, we previously reported that BACE1
+/2
deletion can also rescue impairments in long-term potentiation
(LTP: a measure of synaptic plasticity representing a cellular basis
of learning and memory) at Schaffer collateral-CA1 synapses in
hippocampal slices from 6-month-old 5XFAD transgenic mice
[22]. A growing body of in vitro and in vivo evidence demonstrates
physiological roles of the septohippocampal cholinergic inputs in
positively modulating various forms of long-lasting synaptic
enhancement at CA1 glutamatergic pathways [55,56,57,58].
Therefore, it is interesting to argue that genetic reductions of
BACE1, and consequently of Ab/C99, can exert beneficial effects
in the relatively earlier phases of 5XFAD model possibly by
protecting the cholinergic-glutamatergic functional interactions
during learning and memory processing in the hippocampal
circuitry. The failure of BACE1
+/2 ablation to rescue the
septohippocampal degeneration found in 15–18-month-old
5XFAD mice in parallel with no amelioration of memory function
supports the view that Ab/C99-dependent cholinergic dysfunction
represents a critical mechanism responsible for memory impair-
ments in 5XFAD mice.
In conclusion, the results presented here demonstrate that the
same degree of b-secretase suppression (e.g., 50% by BACE1
+/2
deletion) becomes less efficacious and eventually ineffective in
reducing Ab/C99 accumulation and rescuing cholinergic
neurodegeneration or memory deficits in 5XFAD mice as disease
progresses into the more profound stage that is accompanied by
BACE1 upregulation. Notably, phosphorylation of eIF2a, which
increases age-dependently and induces BACE1 elevation in the
5XFAD model, seems to be important for determining the
abilities of partial BACE1 reduction to improve cholinergic and
mnemonic deficits. In line with the discovery of various BACE1
physiological substrates besides APP such as neuregulins and b-
subunits of the voltage-gated sodium channel, recent studies
reveal some liabilities of complete BACE1 deletion including
hypomyelination and altered synaptic functions or neuronal
activities [4,5,6]. However, these phenotypes are not observed in
BACE1
+/2 knockout mice, suggesting that potential mechanism-
based side effects might occur only in completely abolishing
BACE1 activity but not in partially inhibiting it. Therefore,
strategies combining partial BACE1 suppression with inhibition
of the BACE1-elevating pathway (e.g., eIF2a phosphorylation)
may be useful for increasing the therapeutic benefits while
obviating the potential adverse effects in treating AD and related
memory deficits.
Materials and Methods
Animals
We used 5XFAD transgenic mice (Tg6799 line) that co-express
and co-inherit FAD mutant forms of human APP (the Swedish
mutation: K670N, M671L; the Florida mutation: I716V; the
London mutation: V717I) and PS1 (M146L; L286V) transgenes
under transcriptional control of the neuron-specific mouse Thy-1
promoter [8,28]. Hemizygous 5XFAD transgenic mice (B6/SJL
hybrid background) were crossbred to BACE1 homozygous
knockout (BACE1
2/2) mice (C57BL/6 background, The Jackson
Laboratory, Bar Harbor, ME) [10,59] or C57BL/6 control mice.
The resultant F1 heterozygous BACE1 knockout mice and
hemizygous 5XFAD transgenic mice were further intercrossed,
yielding animals with four different genotypes (wild-type,
BACE1
+/2, 5XFAD
+/2, and BACE1
+/2?5XFAD
+/2) in the F2
progeny. Genotyping was performed by PCR analysis of tail DNA.
All experiments were done blind with respect to the genotype of
the mice at 6 and 15–18 months of age, and were conducted with
the approval of the Nathan Kline Institute Animal Care and Use
Committee (AP2008-268).
Immunoblot analysis
Hemibrain or hippocampal samples were taken from the mice
under deep isoflurane anesthesia and were snap-frozen for
biochemical assays. For Western blot analysis, each sample was
homogenized in 5 volumes of modified RIPA buffer containing
150 mM NaCl, 50 mM Tris HCl (pH 8.0), 1 mM EDTA, 1%
IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS and protease/
phosphatase inhibitor cocktail (Calbiochem, La Jolla, CA), and
centrifuged at 10,000 g for 10 min to remove any insoluble
material. Protein concentrations were determined by a BCA
protein assay kit (Pierce, Rockford, IL), and 20–50 mg of protein
was run on 4–12% NuPAGE gels (Invitrogen, Carlsbad, CA) and
transferred to nitrocellulose membrane. After blocking, mem-
branes were probed with anti-BACE1 (1:1,000, MAB5308,
Millipore, Billerica, MA), anti-full-length APP (1:1,000, 22C11,
MAB348, Millipore), an antibody that recognizes C-terminal
epitope in APP (1:1,000, C1/6.1, kindly provided by Dr. Paul
Mathews, Nathan Kline Institute) to detect the b-secretase-cleaved
C-terminal fragment (C99), anti-phospho-eIF2a (Ser51) (1:1,000,
#3398, Cell Signaling Technology, Danvers, MA), anti-ChAT
(1:1,000, AB144P, Millipore) or anti-b-actin (1:15,000, AC-15,
Sigma, St. Louis, MO), and were incubated with horseradish
peroxidase-conjugated secondary IgG. Immunoblot signals were
visualized by an ECL chemiluminescence substrate reagent kit
(Pierce) and were quantified by densitometric scanning and image
analysis using Quantity One software (Bio-Rad Laboratories,
Hercules, CA).
Brain slice preparation and Sal 003 treatment
After brains were removed from mice following decapitation
under deep anesthesia with isoflurane, sagittal slices (400 mm thick)
between 1.0–2.0 mm from the midline were prepared using a
vibratome (VT1200, Leica Microsystems, Wetzlar, Germany) and
were maintained in an artificial cerebral spinal fluid (aCSF)-filled
holding chamber at room temperature for 1 h. The aCSF
contained (in mM) 124 NaCl, 3 KCl, 2.4 CaCl2, 2 MgCl2, 1.25
NaH2PO4, 26 NaHCO3 and 10 D-glucose, and was equilibrated
with 95% O2 and 5% CO2. Sal 003 (Cat No. 3657, Tocris
Bioscience, Ellisville, MO), a cell-permeable inhibitor of phospha-
tase that dephosphorylates phospho-eIF2a, was dissolved in
DMSO and diluted to 30 mM with aCSF. For drug application,
slices were transferred to the submerged chamber constantly
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were incubated for 1 h in normal aCSF or Sal 003-containing
aCSF, they were homogenized in an ice-cold lysis buffer for
Western blot analysis.
Ab42 ELISA
Sandwich Ab ELISA was performed as described previously
[21,22]. Briefly, each hemibrain sample was extracted in 8X cold
5 M guanidine HCl plus 50 mM Tris HCl (pH 8.0) buffer, and
centrifuged at 20,000 g for 1 h at 4uC to remove insoluble
material. Final guanidine HCl concentrations were below 0.1 M.
Protein concentrations were determined by a BCA kit (Pierce). To
quantitate total levels of cerebral Ab42, supernatant fractions were
analyzed by a well-established human Ab42 ELISA kits
(KHB3441, Invitrogen) according to the protocol of the manu-
facturer. Optical densities at 450 nm of each well were read on a
VersaMax tunable microplate reader (Molecular Devices, Sunny-
vale, CA), and sample Ab42 concentrations were determined by
comparison with the respective standard curves. Ab42 concentra-
tion values were normalized to total brain protein concentrations
and expressed in nanograms per milligram of total protein.
ChAT immunohistochemistry
Mice were transcardially perfused with 4% paraformaldehyde
in phosphate buffered saline (PBS) under deep isoflurane
anesthesia. The brain was removed and sectioned coronally at
40 mm on a vibratome (VT1200, Leica Microsystems), and
successive sections were stored in PBS containing 0.01% sodium
azide at 4uC. Four sections per mouse were stained by the avidin-
biotin peroxidase complex method for immunohistochemical
analysis of ChAT-positive neurons in the Ch1/2 comprising the
medial septum and the vertical limb of the diagonal band. Each
section was separated by ,120 mm and taken at levels between
+1.2 and +0.8 mm anterior to bregma according to the mouse
brain atlas of Franklin and Paxinos [60]. The sections were
incubated overnight at 4uC with polyclonal goat anti-ChAT
antibody (1:200; AB144P, Millipore). The ABC kit (PK-6105,
Vector Laboratories, Burlingame, CA) was utilized with 3,39-
diaminobenzidine tetrahydrochloride as a chromogen to visualize
the reaction product. The sections were then mounted on charged
slides, dehydrated in a series of alcohol, cleared in xylene, and
covered with a coverslip. Light microscopy was conducted on an
Axioskop 2 microscope equipped with an AxioCaM HRc digital
camera (Zeiss, Munich, Germany) for capturing images. After
identified objects following thresholding were individually inspect-
ed by the same investigator in a blinded manner to confirm the
object as a neuron or not, the number of ChAT-positive neurons
in the Ch1/2 was counted using AxioVision imaging software with
the AutoMeasure module (Zeiss). The average of ChAT-positive
neuron number per section from each mouse was used to calculate
group medians.
Spontaneous alternation Y-maze test
Spontaneous alternation performance was tested using a
symmetrical Y-maze, as described previously [7,22]. Each mouse
was placed in the center of the Y-maze and was allowed to explore
freely through the maze during an 8-min session. The sequence
and total number of arms entered were recorded. Arm entry was
considered to be complete when the hind paws of the mouse had
been completely placed in the arm. Percentage alternation is the
number of triads containing entries into all three arms divided by
the maximum possible alternations (the total number of arms
entered minus 2) X 100.
Statistical analysis
The significance of differences between the groups was
determined by a one-way ANOVA and post-hoc Fisher’s PLSD
tests were performed when appropriate. Data were presented as
mean 6 SEM and the level of significance was set for p value less
than 0.05.
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